CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 126 participants.

Also called NCT07761572

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 126 participants (planned count) (from the registry)
Sponsor
Cereno Scientific AB (from the registry)
Registry
  • NCT NCT07761572
  • EU CT 2026-526523-22-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07761572. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-15 (anticipated); primary completion 2029-02-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
Acronym
EPIMODE
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
CS1
Intervention (Drug)
Placebo
Lead sponsor
Cereno Scientific AB (class: industry)

Record details

Record id
cardio:ct-nct07761572
Content hash
5a711a99f23627ff5e3bb0123d19bbf29ea78261eea594b479ac9c6e386001c4